{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:35:33Z","timestamp":1794008133697,"version":"4.8.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Diabetes-Zentrum (DDZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/hypothesis<\/jats:title>\n                    <jats:p>No established blood-based biomarker exists to monitor diabetic sensorimotor polyneuropathy (DSPN) and evaluate treatment response. The neurofilament light chain (NFL), a blood biomarker of neuroaxonal damage in several neurodegenerative diseases, represents a potential biomarker for DSPN. We hypothesised that higher serum NFL levels are associated with prevalent DSPN and nerve dysfunction in individuals recently diagnosed with diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included 423 adults with type 1 and type 2 diabetes and known diabetes duration of less than 1 year from the prospective observational German Diabetes Study cohort. NFL was measured in serum samples of fasting participants in a multiplex approach using proximity extension assay technology. DSPN was assessed by neurological examination, nerve conduction studies and quantitative sensory testing. Associations of serum NFL with DSPN (defined according to the Toronto Consensus criteria) were estimated using Poisson regression, while multivariable linear and quantile regression models were used to assess associations with nerve function measures. In exploratory analyses, other biomarkers in the multiplex panel were also analysed similarly to NFL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      DSPN was found in 16% of the study sample. Serum NFL levels increased with age. After adjustment for age, sex, waist circumference, height, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      , known diabetes duration, diabetes type, cholesterol, eGFR, hypertension, CVD, use of lipid-lowering drugs and use of non-steroidal anti-inflammatory drugs, higher serum NFL levels were associated with DSPN (RR [95% CI] per 1-normalised protein expression increase, 1.92 [1.50, 2.45],\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.0001), slower motor (all\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.0001) and sensory (all\n                      <jats:italic>p<\/jats:italic>\n                      \u22640.03) nerve conduction velocities, lower sural sensory nerve action potential (\n                      <jats:italic>p<\/jats:italic>\n                      =0.0004) and higher thermal detection threshold to warm stimuli (\n                      <jats:italic>p<\/jats:italic>\n                      =0.023 and\n                      <jats:italic>p<\/jats:italic>\n                      =0.004 for hand and foot, respectively). There was no evidence for associations between other neurological biomarkers and DSPN or nerve function measures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>Our findings in individuals recently diagnosed with diabetes provide new evidence associating higher serum NFL levels with DSPN and peripheral nerve dysfunction. The present study advocates NFL as a potential biomarker for DSPN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00125-022-05846-8","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T08:11:40Z","timestamp":1670487100000},"page":"579-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2910-1142","authenticated-orcid":false,"given":"Haifa","family":"Maalmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Strom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-6195","authenticated-orcid":false,"given":"Agnese","family":"Petrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-6827","authenticated-orcid":false,"given":"Stefanie M.","family":"Hauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6636-1373","authenticated-orcid":false,"given":"Klaus","family":"Strassburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-5869","authenticated-orcid":false,"given":"Oliver","family":"Kuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-9585","authenticated-orcid":false,"given":"Oana-Patricia","family":"Zaharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1446-6592","authenticated-orcid":false,"given":"Gidon J.","family":"B\u00f6nhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-1740","authenticated-orcid":false,"given":"Wolfgang","family":"Rathmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1419-7177","authenticated-orcid":false,"given":"Sandra","family":"Trenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-324X","authenticated-orcid":false,"given":"Volker","family":"Burkart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-8168","authenticated-orcid":false,"given":"Julia","family":"Szendroedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8956-3552","authenticated-orcid":false,"given":"Dan","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8200-6382","authenticated-orcid":false,"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2050-093X","authenticated-orcid":false,"given":"Christian","family":"Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the GDS Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"issue":"4","key":"5846_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jdi.13401","volume":"12","author":"D Ziegler","year":"2021","unstructured":"Ziegler D, Papanas N, Schnell O et al (2021) Current concepts in the management of diabetic polyneuropathy. J Diabetes Investig 12(4):464\u2013475. https:\/\/doi.org\/10.1111\/jdi.13401","journal-title":"J Diabetes Investig"},{"issue":"5","key":"5846_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/dmrr.2397","volume":"29","author":"AJ Boulton","year":"2013","unstructured":"Boulton AJ, Kempler P, Ametov A, Ziegler D (2013) Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev 29(5):327\u2013333. https:\/\/doi.org\/10.1002\/dmrr.2397","journal-title":"Diabetes Metab Res Rev"},{"key":"5846_CR3","doi-asserted-by":"publisher","first-page":"109063","DOI":"10.1016\/j.diabres.2021.109063","volume":"186","author":"D Ziegler","year":"2021","unstructured":"Ziegler D, Tesfaye S, Spallone V et al (2021) Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Res Clin Pract 186:109063. https:\/\/doi.org\/10.1016\/j.diabres.2021.109063","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"5846_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"R Pop-Busui","year":"2017","unstructured":"Pop-Busui R, Boulton AJ, Feldman EL et al (2017) Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care 40(1):136\u2013154. https:\/\/doi.org\/10.2337\/dc16-2042","journal-title":"Diabetes Care"},{"issue":"5","key":"5846_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00125-020-05085-9","volume":"63","author":"BC Callaghan","year":"2020","unstructured":"Callaghan BC, Gallagher G, Fridman V, Feldman EL (2020) Diabetic neuropathy: what does the future hold? Diabetologia 63(5):891\u2013897. https:\/\/doi.org\/10.1007\/s00125-020-05085-9","journal-title":"Diabetologia"},{"issue":"8","key":"5846_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S2213-8587(14)70067-1","volume":"2","author":"RA Malik","year":"2014","unstructured":"Malik RA (2014) Why are there no good treatments for diabetic neuropathy? Lancet Diabetes Endocrinol 2(8):607\u2013609. https:\/\/doi.org\/10.1016\/S2213-8587(14)70067-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"5846_CR7","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.2337\/diacare.25.11.2010","volume":"25","author":"AL Carrington","year":"2002","unstructured":"Carrington AL, Shaw JE, Van Schie CH, Abbott CA, Vileikyte L, Boulton AJ (2002) Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care 25(11):2010\u20132015. https:\/\/doi.org\/10.2337\/diacare.25.11.2010","journal-title":"Diabetes Care"},{"key":"5846_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ceb.2020.10.011","volume":"68","author":"P Bomont","year":"2021","unstructured":"Bomont P (2021) The dazzling rise of neurofilaments: physiological functions and roles as biomarkers. Curr Opin Cell Biol 68:181\u2013191. https:\/\/doi.org\/10.1016\/j.ceb.2020.10.011","journal-title":"Curr Opin Cell Biol"},{"key":"5846_CR9","doi-asserted-by":"publisher","first-page":"820105","DOI":"10.3389\/fcell.2021.820105","volume":"9","author":"MT Sainio","year":"2021","unstructured":"Sainio MT, Rasila T, Molchanova SM et al (2021) Neurofilament light regulates axon caliber, synaptic activity, and organelle trafficking in cultured human motor neurons. Front Cell Dev Biol 9:820105. https:\/\/doi.org\/10.3389\/fcell.2021.820105","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"5846_CR10","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/brain\/awaa098","volume":"143","author":"AR Gafson","year":"2020","unstructured":"Gafson AR, Barth\u00e9lemy NR, Bomont P et al (2020) Neurofilaments: neurobiological foundations for biomarker applications. Brain 143(7):1975\u20131998. https:\/\/doi.org\/10.1093\/brain\/awaa098","journal-title":"Brain"},{"key":"5846_CR11","doi-asserted-by":"publisher","first-page":"642384","DOI":"10.3389\/fnins.2021.642384","volume":"15","author":"C Ferreira-Atuesta","year":"2021","unstructured":"Ferreira-Atuesta C, Reyes S, Giovanonni G, Gnanapavan S (2021) The evolution of neurofilament light chain in multiple sclerosis. Front Neurosci 15:642384. https:\/\/doi.org\/10.3389\/fnins.2021.642384","journal-title":"Front Neurosci"},{"key":"5846_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.conb.2020.02.001","volume":"61","author":"BA Gordon","year":"2020","unstructured":"Gordon BA (2020) Neurofilaments in disease: what do we know? Curr Opin Neurobiol 61:105\u2013115. https:\/\/doi.org\/10.1016\/j.conb.2020.02.001","journal-title":"Curr Opin Neurobiol"},{"issue":"1","key":"5846_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12974-020-01737-0","volume":"17","author":"P Altmann","year":"2020","unstructured":"Altmann P, De Simoni D, Kaider A et al (2020) Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barre syndrome. J Neuroinflammation 17(1):86. https:\/\/doi.org\/10.1186\/s12974-020-01737-0","journal-title":"J Neuroinflammation"},{"issue":"7","key":"5846_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/annrheumdis-2017-212045","volume":"77","author":"A Bischof","year":"2018","unstructured":"Bischof A, Manigold T, Barro C et al (2018) Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann Rheum Dis 77(7):1093\u20131094. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212045","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5846_CR15","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1007\/s00415-021-10537-2","volume":"268","author":"Y Fukami","year":"2021","unstructured":"Fukami Y, Iijima M, Koike H, Yamada S, Hashizume A, Katsuno M (2021) Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. J Neurol 268(10):3835\u20133844. https:\/\/doi.org\/10.1007\/s00415-021-10537-2","journal-title":"J Neurol"},{"issue":"1","key":"5846_CR16","doi-asserted-by":"publisher","first-page":"fcab018","DOI":"10.1093\/braincomms\/fcab018","volume":"3","author":"J Godelaine","year":"2021","unstructured":"Godelaine J, De Schaepdryver M, Bossuyt X, Van Damme P, Claeys KG, Poesen K (2021) Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Commun 3(1):fcab018. https:\/\/doi.org\/10.1093\/braincomms\/fcab018","journal-title":"Brain Commun"},{"issue":"5","key":"5846_CR17","doi-asserted-by":"publisher","first-page":"e02084","DOI":"10.1002\/brb3.2084","volume":"11","author":"T Hayashi","year":"2021","unstructured":"Hayashi T, Nukui T, Piao JL et al (2021) Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Behav 11(5):e02084. https:\/\/doi.org\/10.1002\/brb3.2084","journal-title":"Brain Behav"},{"issue":"6","key":"5846_CR18","doi-asserted-by":"publisher","first-page":"e154395","DOI":"10.1172\/jci.insight.154395","volume":"7","author":"P Huehnchen","year":"2022","unstructured":"Huehnchen P, Schinke C, Bangemann N et al (2022) Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 7(6):e154395. https:\/\/doi.org\/10.1172\/jci.insight.154395","journal-title":"JCI Insight"},{"issue":"1","key":"5846_CR19","doi-asserted-by":"publisher","first-page":"7995","DOI":"10.1038\/s41598-020-64511-5","volume":"10","author":"S-H Kim","year":"2020","unstructured":"Kim S-H, Choi MK, Park NY et al (2020) Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 10(1):7995. https:\/\/doi.org\/10.1038\/s41598-020-64511-5","journal-title":"Sci Rep"},{"issue":"1","key":"5846_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/13506129.2020.1815696","volume":"28","author":"J Louwsma","year":"2021","unstructured":"Louwsma J, Brunger AF, Bijzet J et al (2021) Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid 28(1):50\u201355. https:\/\/doi.org\/10.1080\/13506129.2020.1815696","journal-title":"Amyloid"},{"issue":"2","key":"5846_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","volume":"27","author":"LF Maia","year":"2020","unstructured":"Maia LF, Maceski A, Concei\u00e7\u00e3o I et al (2020) Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid 27(2):97\u2013102. https:\/\/doi.org\/10.1080\/13506129.2019.1708716","journal-title":"Amyloid"},{"issue":"3","key":"5846_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jns.12279","volume":"23","author":"S Mariotto","year":"2018","unstructured":"Mariotto S, Farinazzo A, Magliozzi R, Alberti D, Monaco S, Ferrari S (2018) Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst 23(3):174\u2013177. https:\/\/doi.org\/10.1111\/jns.12279","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"5846_CR23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/ene.14689","volume":"28","author":"E Millere","year":"2021","unstructured":"Millere E, Rots D, Simr\u00e9n J et al (2021) Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. Eur J Neurol 28(3):974\u2013981. https:\/\/doi.org\/10.1111\/ene.14689","journal-title":"Eur J Neurol"},{"issue":"6","key":"5846_CR24","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","volume":"90","author":"\u00c5 Sandelius","year":"2018","unstructured":"Sandelius \u00c5, Zetterberg H, Blennow K et al (2018) Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90(6):e518\u2013e524. https:\/\/doi.org\/10.1212\/WNL.0000000000004932","journal-title":"Neurology"},{"issue":"2","key":"5846_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jns.12319","volume":"24","author":"GGA van Lieverloo","year":"2019","unstructured":"van Lieverloo GGA, Wieske L, Verhamme C et al (2019) Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 24(2):187\u2013194. https:\/\/doi.org\/10.1111\/jns.12319","journal-title":"J Peripher Nerv Syst"},{"key":"5846_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.expneurol.2018.06.005","volume":"307","author":"C Meregalli","year":"2018","unstructured":"Meregalli C, Fumagalli G, Alberti P et al (2018) Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Exp Neurol 307:129\u2013132. https:\/\/doi.org\/10.1016\/j.expneurol.2018.06.005","journal-title":"Exp Neurol"},{"issue":"7","key":"5846_CR27","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00204-020-02755-w","volume":"94","author":"C Meregalli","year":"2020","unstructured":"Meregalli C, Fumagalli G, Alberti P et al (2020) Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of chemotherapy-induced peripheral neurotoxicity. Arch Toxicol 94(7):2517\u20132522. https:\/\/doi.org\/10.1007\/s00204-020-02755-w","journal-title":"Arch Toxicol"},{"issue":"1","key":"5846_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/toxsci\/kfab122","volume":"185","author":"T Sano","year":"2021","unstructured":"Sano T, Masuda Y, Yasuno H, Shinozawa T, Watanabe T, Kakehi M (2021) Blood neurofilament light chain as a potential biomarker for central and peripheral nervous toxicity in rats. Toxicol Sci 185(1):10\u201318. https:\/\/doi.org\/10.1093\/toxsci\/kfab122","journal-title":"Toxicol Sci"},{"issue":"12","key":"5846_CR29","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1007\/s00125-021-05557-6","volume":"64","author":"J Morgenstern","year":"2021","unstructured":"Morgenstern J, Groener JB, Jende JME et al (2021) Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy. Diabetologia 64(12):2843\u20132855. https:\/\/doi.org\/10.1007\/s00125-021-05557-6","journal-title":"Diabetologia"},{"issue":"6","key":"5846_CR30","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1007\/s11033-014-3270-y","volume":"41","author":"A Celikbilek","year":"2014","unstructured":"Celikbilek A, Tanik N, Sabah S et al (2014) Elevated neurofilament light chain (NFL) mRNA levels in prediabetic peripheral neuropathy. Mol Biol Rep 41(6):4017\u20134022. https:\/\/doi.org\/10.1007\/s11033-014-3270-y","journal-title":"Mol Biol Rep"},{"key":"5846_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12933-016-0374-9","volume":"15","author":"J Szendroedi","year":"2016","unstructured":"Szendroedi J, Saxena A, Weber KS et al (2016) Cohort profile: the German Diabetes Study (GDS). Cardiovasc Diabetol 15:59. https:\/\/doi.org\/10.1186\/s12933-016-0374-9","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 1","key":"5846_CR32","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc18-S002","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association (2018) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1):S13\u2013s27. https:\/\/doi.org\/10.2337\/dc18-S002","journal-title":"Diabetes Care"},{"issue":"10","key":"5846_CR33","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1093\/brain\/awab330","volume":"144","author":"D Ziegler","year":"2021","unstructured":"Ziegler D, Bonhof GJ, Strom A et al (2021) Progression and regression of nerve fibre pathology and dysfunction early in diabetes over 5 years. Brain 144(10):3251\u20133263. https:\/\/doi.org\/10.1093\/brain\/awab330","journal-title":"Brain"},{"issue":"11","key":"5846_CR34","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1038\/emm.2017.173","volume":"49","author":"A Strom","year":"2017","unstructured":"Strom A, Kaul K, Br\u00fcggemann J et al (2017) Lower serum extracellular superoxide dismutase levels are associated with polyneuropathy in recent-onset diabetes. Exp Mol Med 49(11):e394. https:\/\/doi.org\/10.1038\/emm.2017.173","journal-title":"Exp Mol Med"},{"issue":"2","key":"5846_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/BF00400697","volume":"36","author":"MJ Young","year":"1993","unstructured":"Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH (1993) A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36(2):150\u2013154. https:\/\/doi.org\/10.1007\/BF00400697","journal-title":"Diabetologia"},{"issue":"7","key":"5846_CR36","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/dmrr.1226","volume":"27","author":"PJ Dyck","year":"2011","unstructured":"Dyck PJ, Albers JW, Andersen H et al (2011) Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 27(7):620\u2013628. https:\/\/doi.org\/10.1002\/dmrr.1226","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"5846_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367(1):20\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1114248","journal-title":"N Engl J Med"},{"issue":"11","key":"5846_CR38","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.2337\/db18-0060","volume":"67","author":"C Herder","year":"2018","unstructured":"Herder C, Kannenberg JM, Carstensen-Kirberg M et al (2018) A systemic inflammatory signature reflecting cross talk between innate and adaptive immunity is associated with incident polyneuropathy: KORA F4\/FF4 study. Diabetes 67(11):2434\u20132442. https:\/\/doi.org\/10.2337\/db18-0060","journal-title":"Diabetes"},{"issue":"4","key":"5846_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1530\/EJE-15-1010","volume":"174","author":"I Schamarek","year":"2016","unstructured":"Schamarek I, Herder C, Nowotny B et al (2016) Adiponectin, markers of subclinical inflammation and nerve conduction in individuals with recently diagnosed type 1 and type 2 diabetes. Eur J Endocrinol 174(4):433\u2013443. https:\/\/doi.org\/10.1530\/EJE-15-1010","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"5846_CR40","doi-asserted-by":"publisher","first-page":"e001698","DOI":"10.1136\/bmjdrc-2020-001698","volume":"9","author":"H Maalmi","year":"2021","unstructured":"Maalmi H, Wouters K, Savelberg H et al (2021) Associations of cells from both innate and adaptive immunity with lower nerve conduction velocity: the Maastricht Study. BMJ Open Diabetes Res Care 9(1):e001698. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001698","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"5846_CR41","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/opo.12131","volume":"34","author":"RA Armstrong","year":"2014","unstructured":"Armstrong RA (2014) When to use the Bonferroni correction. Ophthalmic Physiol Opt 34(5):502\u2013508. https:\/\/doi.org\/10.1111\/opo.12131","journal-title":"Ophthalmic Physiol Opt"},{"issue":"4","key":"5846_CR42","first-page":"241","volume":"45","author":"A Cappellari","year":"2005","unstructured":"Cappellari A, Airaghi L, Capra R et al (2005) Early peripheral nerve abnormalities in impaired glucose tolerance. Electromyogr Clin Neurophysiol 45(4):241\u2013244","journal-title":"Electromyogr Clin Neurophysiol"},{"issue":"1-2","key":"5846_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1900\/rds.2015.12.29","volume":"12","author":"PR Vas","year":"2015","unstructured":"Vas PR, Sharma S, Rayman G (2015) Distal sensorimotor neuropathy: improvements in diagnosis. Rev Diabet Stud 12(1-2):29\u201347. https:\/\/doi.org\/10.1900\/rds.2015.12.29","journal-title":"Rev Diabet Stud"},{"issue":"2","key":"5846_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1212\/01.wnl.0000149522.32823.ea","volume":"64","author":"JD England","year":"2005","unstructured":"England JD, Gronseth GS, Franklin G et al (2005) Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 64(2):199\u2013207. https:\/\/doi.org\/10.1212\/01.wnl.0000149522.32823.ea","journal-title":"Neurology"},{"issue":"10","key":"5846_CR45","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s00415-020-09949-3","volume":"267","author":"S Mariotto","year":"2020","unstructured":"Mariotto S, Carta S, Bozzetti S et al (2020) Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels. J Neurol 267(10):2881\u20132887. https:\/\/doi.org\/10.1007\/s00415-020-09949-3","journal-title":"J Neurol"},{"issue":"1","key":"5846_CR46","first-page":"3","volume":"42","author":"J Valls-Canals","year":"2002","unstructured":"Valls-Canals J, Povedano M, Montero J, Pradas J (2002) Diabetic polyneuropathy. Axonal or demyelinating? Electromyogr Clin Neurophysiol 42(1):3\u20136","journal-title":"Electromyogr Clin Neurophysiol"},{"issue":"10","key":"5846_CR47","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2337\/dc10-1303","volume":"33","author":"S Tesfaye","year":"2010","unstructured":"Tesfaye S, Boulton AJ, Dyck PJ et al (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33(10):2285\u20132293. https:\/\/doi.org\/10.2337\/dc10-1303","journal-title":"Diabetes Care"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-022-05846-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-022-05846-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-022-05846-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T06:46:23Z","timestamp":1675233983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-022-05846-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["5846"],"URL":"https:\/\/doi.org\/10.1007\/s00125-022-05846-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"31 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}